CRRA, FRE, OPGX, RTK, YMI, DANR OTCPicks.com Stocks to Watch for Tuesday, August 11th

Our Stocks to Watch include Capital Resource Alliance Inc. (OTCBB: CRRA), Freddie Mac (NYSE: FRE), Optigenex Inc. (OTC: OPGX), Rentech Inc. (Amex: RTK), YM BioSciences Inc. (Amex: YMI) and Dana Resources (OTCBB: DANR).

 

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

 

CAPITAL RESOURCE ALLIANCE INCORPORATED (OTCBB: CRRA)

"Up 1,033.33% on Monday"

 

Detailed Quote: http://www.otcpicks.com/quotes/CRRA.php

 

Capital Resource Alliance, Inc. engages in the acquisition and exploration of mineral properties in Canada. It holds 100% interest in the Long Lake property, which consists of 2 blocks of mineral claims comprising 21 units and is located in the Abrey Township, northwestern Ontario. The company intends to explore for economic reserves of gold, silver, and/or copper. Capital Resource Alliance, Inc. was founded in 2000 and is based in Calgary, Canada.

 

CRRA News:

 

August 10 - Capital Resource Alliance Announces Letter of Intent to Acquire Revolutionary New Building System

 

Mr. Frederick Fitzgerald, President and Chief Operating Officer of Capital Resource Alliance Inc. (OTCBB: CRRA) announced the acquisition of the principal assets of Engineered Construction Solutions Inc., of Calgary. Terms of the purchase are Forty Million shares of Capital Resource Alliance Inc. common stock at closing plus an undertaking to use every effort to supply up to $500,000 working capital on or before the closing date of October 31, 2009.

 

The purchased assets consist of all the proprietary technology and intellectual property involved with the manufacture and marketing of "WonderWall" a revolutionary building system that involves on site creation of long lasting, low cost housing, schools, commercial buildings and storage facilities. The foundation of the building components is a propriety ceramic foam manufactured on site, quickly and economically. The resultant building product is fire and water proof, virtually indestructible under normal conditions and extremely cost affective. Several foreign governments and commercial enterprises have indicated active interest in this new building technology.

 

Mr. Ray Gordon, President and CEO of Engineered Construction Solutions Inc. has agreed to join the Board of Capital Resource Alliance Inc. and assume the office of President and CEO of the purchasing corporation. Frederick Fitzgerald will remain as a director and retain his office of Secretary/Treasurer.

 

FREDDIE MAC (NYSE: FRE)

"Up 128.38% on Monday"

 

Detailed Quote: http://www.otcpicks.com/quotes/FRE.php

 

Freddie Mac purchases residential mortgages and mortgage-related securities in the secondary mortgage market and securitizes them into mortgage-related securities that can be sold to investors. It operates in three segments: Investments, Single-family Guarantee, and Multifamily. The Investments segment invests primarily in mortgage-related securities and single-family mortgage loans; purchases mortgage loans and mortgage-related securities; and issues short- and long-term debt in the capital markets. The Single-Family Guarantee segment engages in the purchase of single-family mortgages in the primary mortgage market, primarily through its guarantor swap program; securitizes certain mortgages; issues mortgage-related securities that can be sold; and guarantees the payment of principal and interest on single-family mortgage-related securities. The Multifamily segment purchases multifamily mortgages; and guarantees the payment of principal and interest on multifamily mortgage-related securities and mortgages underlying multifamily housing revenue bonds. This segment also holds equity investments in various limited partnerships that sponsor low- and moderate-income multifamily rental apartments. The company primarily serves lenders in the primary mortgage market that originate mortgages for homeowners and apartment owners, including mortgage banking companies, commercial banks, savings banks, community banks, credit unions, state and local housing finance agencies, and savings and loan associations in the United States. Freddie Mac was founded in 1970 and is based in McLean, Virginia.

 

FRE News:

 

August 7 - Freddie Mac Releases Second Quarter 2009 Financial Results

 

Summary

 

* Net income for the second quarter of 2009 was $768 million. After the dividend payment of $1.1 billion to the U.S. Department of the Treasury on the senior preferred stock, net loss per diluted common share was $0.11 for the quarter.

 

* Net worth at June 30, 2009 was $8.2 billion. As a result of the positive net worth, no additional funding from the U.S. Department of the Treasury was required under the terms of the Senior Preferred Stock Purchase Agreement for the second quarter. The positive net worth includes a $5.1 billion increase to total equity reflecting the April 1, 2009 adoption of FSP FAS 115-2 and FAS 124-2 relating to accounting for security impairments.

 

The second quarter 2009 results were primarily driven by:

 

* Net interest income of $4.3 billion;

 

* Gains on the company's derivative portfolio and guarantee asset of $4.2 billion, mainly related to net mark-to-market gains due to increases in long-term interest rates;

 

* Net impairment of available-for-sale securities recognized in earnings of $2.2 billion, also reflecting the adoption of FSP FAS 115-2 and FAS 124-2; and

 

* Provision for credit losses of $5.2 billion.

 

* Freddie Mac continued to support the recovery of the housing market. During the second quarter of 2009, the company:

 

* Provided $171 billion of liquidity to the mortgage market, helping to finance more than 720,000 single-family homes and nearly 100,000 units of rental housing;

 

* Helped refinance approximately 28,500 loans under the Freddie Mac Relief Refinance Mortgage (SM); and

 

* Helped approximately 45,000 borrowers stay in their homes or sell their properties, including approximately 16,000 borrowers who were placed in trial period payment plans under the Home Affordable Modification program.

 

Freddie Mac (NYSE: FRE) reported net income of $768 million for the quarter ended June 30, 2009, compared to a net loss of $9.9 billion for the quarter ended March 31, 2009. After the dividend payment of $1.1 billion on its senior preferred stock to the U.S. Department of the Treasury (Treasury), Freddie Mac reported a net loss per diluted common share of $0.11 in the second quarter of 2009, compared to a net loss per diluted common share of $3.14 in the first quarter of 2009.

 

Freddie Mac had a positive net worth of $8.2 billion at June 30, 2009. As a result, no additional funding was required from Treasury under the terms of the Senior Preferred Stock Purchase Agreement (Purchase Agreement) for the second quarter.

 

"We are pleased that our financial results allowed us to finish the quarter with a positive net worth, meaning we will not need to request any additional financial support from the government at this time. However, we recognize that our financial results for the quarter include one-time accounting adjustments and mark-to-market gains that are subject to change in future periods," said Freddie Mac Interim Chief Executive Officer John Koskinen. "While we are seeing some early signs pointing to a housing recovery — including a modest uptick in house prices in some markets — our outlook remains cautious due to rising foreclosures, growing unemployment, tight lending standards and buyers' reluctance to re-enter the market.

 

"Our role in the Obama Administration's recovery efforts has been focused on helping to stem the foreclosure crisis. In the first half of the year, we were able to help more than 85,000 distressed borrowers avoid foreclosure, and we helped an additional 1 million homeowners lower their mortgage payments through refinancing. The Making Home Affordable program is ramping up and Freddie Mac employees are dedicated to working with our borrowers to help them understand their options and with our servicers to quickly increase their infrastructure and capacity.

 

"On another positive note, we look forward to welcoming our new CEO Ed Haldeman to Freddie Mac. I'm confident that under Ed's leadership we will continue to play a leading role in the recovery of the housing market, while building a stronger foundation for our future," Koskinen said.

 

OPTIGENEX INCORPORATED (OTC: OPGX)

"Up 100.00% on Monday"

 

Detailed Quote: http://www.otcpicks.com/quotes/OPGX.php 

 

Optigenex inc. is a formulator, distributor and provider of proprietary next generation skin care, supplements and bulk ingredient featuring AC-11® (Formerly known as C-MED-100®) a patented compound as it core product. AC- 11® is the bioactive, water soluble form of the medicinal herb Uncaria tomentosa.

 

OPGX News:

 

July 28 - Optigenex Inc. Announces Rollout of Activar® AC-11® Oral Supplements and Activar® AC-11® Next Generation Skin Care Products in Turkey Through Its Middle Eastern Distribution Partner Ekson Farma, Istanbul

 

Company Expects Commercial Sales to Begin in Early Fall 2009 Through Pharmacies and Other Healthcare Distribution Channels (Financial Terms Were Not Disclosed)

 

Optigenex Inc. (OTC: OPGX) announced that its partner Ekson Farma is prepared to launch its family of AC-11® oral supplements and skin care products under the brand name Activar® for distribution throughout the major pharmacies in Turkey. Under an exclusive license signed in early 2008, Ekson has invested significant capital, resources and time in determining market acceptance of Optigenex's patented technology and has also devoted considerable efforts towards clinical and scientific research to broaden the market applications for its unique anti-aging products. The agreement and subsequent commercialization by Ekson sets the stage for the introduction of AC-11® to educated and health-conscious Turkish consumers and represents another important strategic initiative in the company's plans to establish AC-11® as a recognized international brand.

 

All-natural, and standardized at a minimum of 8 per cent Carboxy Alkyl Esters ("CAEs(TM)"), AC-11® is the only patented aqueous extract of the Uncaria species that can make the following therapeutic claims ("DNA repair, Immune enhancement and Inhibition of pro-inflammatory agents") which are validated by a broad spectrum of scientific and clinical studies.

 

AC-11® already has gained a major foothold in Japan and has been introduced in other select territories of Asia as a branded ingredient used by over 100 manufacturers and distributors in a variety of anti-aging cosmetic, cosmeceutical and dietary supplement products. With their regional alliance together, Optigenex and Middle Eastern based Ekson Farma anticipate similar market penetration, growth and expansion for AC-11®

 

Daniel Zwiren, president and CEO of Optigenex Inc., said, "We are delighted to have a company with the scientific pedigree and reputation of Ekson Farma as part of our growing list of marketing and distribution partners. Moreover, we believe the unique scientific properties of AC-11® along with Ekson's research will allow us to grow our business rapidly in this key geographic region."

 

Doctor Yaman Er, president of Ekson Farma, added, "We are very pleased with the reception AC-11® has received and attribute this attention to the key differentiators of AC-11® supported by clinical and scientific studies. Those studies validate the efficacy of this all-natural ingredient, which is harvested in the Amazon Rainforest and manufactured by Centroflora Group Botucatu, Brazil. Consumer demand in our market is driven by new and result-oriented technologies. We believe our alliance with Optigenex provides us with the opportunity to introduce Turkey and the Middle East to the next major brand in oral and topical applications."

 

ABOUT EKSON FARMA

 

Founded in 1994, Ekson Farma is an applied sciences and marketing company focused on providing wellness solutions and related technologies to physicians, pharmacies and the general medical community. Ekson's strategy is to select superior and innovative products validated by clinical and scientific studies, establish consumer and physician acceptance through test marketing and ultimately distribute those products with the goal of improving the quality of life for health conscious consumers and patients. Ekson through its collaboration with research partner OKSANTE LABORATORIES is noted for its development of diagnostic tools utilizing DNA sequencing and molecular diagnostics with an emphasis on early detection of disease and DNA mutations.

 

RENTECH INCORPORATED (AMEX: RTK)

"Up 112.90% on Monday"

 

Detailed Quote: http://www.otcpicks.com/quotes/RTK.php

 

Incorporated in 1981, Rentech provides clean energy solutions. The Rentech Process is a patented and proprietary technology that converts synthesis gas from biomass and fossil resources into hydrocarbons that can be processed and upgraded into ultra-clean synthetic fuels, specialty waxes and chemicals. Rentech Energy Midwest Corporation, the Company’s wholly-owned subsidiary, manufactures and sells fertilizer products including ammonia, urea ammonia nitrate, urea granule and urea solution to the corn-belt region.

 

RTK News:

 

August 10 - Rentech Announces Record Earnings of 22 Cents per Share for Third Quarter of Fiscal 2009

 

Company Projects Positive EPS for FY 2009 and Increases Guidance for Consolidated and REMC EBITDA

 

Rentech, Inc. (Amex: RTK) announced results for its third quarter of fiscal year 2009 ended June 30. The Company also issued new guidance for consolidated earnings per share and increased previously provided financial guidance for the 2009 fiscal year.

 

For the third quarter of fiscal year 2009 ended June 30, Rentech reported net income applicable to common shareholders of $36.1 million, or $0.22 per share. This compares to a net loss applicable to common shareholders of $7.8 million, or $0.05 per share, for the comparable period in fiscal year 2008.

 

Rentech reported revenue of $91.4 million for the third quarter of fiscal year 2009, up from $60.4 million for the comparable quarter in the prior year. The increase resulted from higher product pricing and record shipments during the quarter as favorable weather conditions allowed the realization of revenue on significant volumes shipped. Shipments during the second fiscal quarter had been delayed by bad weather.

 

Rentech projects that its earnings per share will be positive for fiscal year 2009. Rentech is increasing its consolidated EBITDA guidance for fiscal year 2009 to greater than $25 million compared to previous guidance of $15 million. The Company has also increased fiscal year 2009 EBITDA guidance for its wholly-owned nitrogen fertilizer business, Rentech Energy Midwest Corporation (REMC), to greater than $65 million from previous guidance of $65 million. In addition to the strong results for the quarter, factors that the Company considered in increasing guidance included: significant pre-sales of fertilizer products for the remainder of the fiscal year; natural gas prices that are forecasted to remain at lower than budgeted levels; and demand for nitrogen products driven by continued strong prospects for planted corn acreage. EBITDA is a non-GAAP measure. Further explanation of this non-GAAP measure and a computation of consolidated EBITDA and EBITDA at REMC have been included below in this press release.

 

Selling, general and administrative (SG&A) expenses were $6.0 million for the third quarter of fiscal year 2009, down from $8.3 million for the third quarter of the prior year. Research and development (R&D) expenses for the third quarter of fiscal year 2009 were $7.2 million, down from $15.8 million for the third quarter of the prior year. The decrease in R&D expenses was primarily due to the completion of construction of the Company’s Product Demonstration Unit (PDU) in the prior fiscal year. Current period R&D expenses were attributable to costs associated with operating the PDU, expenses incurred for work on advanced catalysts, catalyst separation from crude wax, process optimization, and product upgrading. R&D expenses for the current period also included a one-time tax accrual of $2.9 million related to the construction of the PDU.

 

Rentech reported revenue of $158.3 million for the nine months ended June 30, 2009, compared to $136.4 million for the comparable period in the prior year. SG&A expenses were $18.7 million for the first nine months of fiscal year 2009, down from $26.1 million for the comparable period in the prior year. R&D expenses for the current period were $16.6 million, down from $53.9 million for the comparable period in the prior year. As noted previously, the decrease was primarily due to the completion of construction of the PDU in the prior fiscal year.

 

As of June 30, 2009, Rentech had cash and cash equivalents of $38.9 million on a consolidated basis.

 

Commenting on the third quarter results for fiscal year 2009, Dan Cohrs, Executive Vice President and CFO of Rentech, stated, “We are pleased to report our first profitable quarter ever. The cost reductions we implemented in addition to exceptional management of our fertilizer business have provided us with a foundation from which we can continue to execute on our alternative energy strategy.”

 

Mr. Cohrs continued, “We believe Rentech is well-positioned to capture the opportunities that have resulted from the approval of our jet fuel for commercial aviation as well as from the renewable power and low carbon fuel mandates in California.”

 

The Company will hold a conference call on Tuesday, August 11, at 10:00 a.m. PDT at which time Rentech's senior management will review the Company's financial results for this period and provide an update on corporate developments. Callers may listen to the live presentation, which will be followed by a question and answer segment, by dialing 800-926-9801 or 212-231-2903. An audio webcast of the call will be available at www.rentechinc.com within the Investor Relations portion of the site under the Presentations section. A replay will be available by audio webcast and teleconference from 1:00 p.m. PDT on August 11 through 1:00 p.m. PDT on August 18. The replay teleconference will be available by dialing 800-633-8284 or 402-977-9140 and the reservation number 21432611.

 

YM BIOSCIENCES INCORPORATED (AMEX: YMI)

"Up 58.59% on Monday"

 

Detailed Quote: http://www.otcpicks.com/quotes/YMI.php

 

YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody™, and AeroLEF®, a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

 

YMI News:

 

August 10 - YM Biosciences USA Receives Clearance From Us Treasury Department to Extend Clinical Program for Nimotuzumab

 

YM BioSciences Inc. (Amex: YMI) (TSX: YM, AIM: YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today announced that its wholly-owned subsidiary, YM BioSciences USA Inc. (YM-USA) has received a license from the US Department of the Treasury's Office of Foreign Assets Control (OFAC) to further develop its lead product, nimotuzumab, for patients with solid tumor cancers in the United States.

 

"This license from OFAC to develop nimotuzumab in any cancer indication is a major step forward in our US development program and will allow us to immediately discuss our IND submissions with the FDA to include US patients in our randomized, double-blinded lung cancer and brain metastases trials," said David Allan, Chairman and CEO of YM BioSciences. "Our development plans may also include extending some of the Phase III trials being conducted worldwide into the US. There are quantifiable physical, emotional and financial costs that result from the numerous and severe toxicities of the currently available EGFR-targeting drugs which are not evident with the administration of our drug. Nimotuzumab has been demonstrating efficacy in trials throughout the world and we are very pleased that US patients will now have the opportunity to receive the drug and that a broader group of US oncologists will gain experience with it. Our goal is to bring this therapeutic option, already approved for marketing in 18 countries, to patients in the US as rapidly as possible."

 

Mr. Allan added, "We have also applied to OFAC for a license to make nimotuzumab available to US patients upon marketing approval by the FDA. This is consistent with a 2009 Staff Report to the US Senate Committee on Foreign Relations (SCFR) entitled 'Changing Cuba Policy - In the United States' National Interest,' which recommended pharmaceutical imports from Cuba's rapidly developing biotech industry. We are most appreciative of the extensive support we have received for our application from SCFR Chairman Senator John Kerry (D-MA), Western Hemisphere Subcommittee Chairman Senator Chris Dodd (D-CT) and SCFR Ranking Member Senator Richard Lugar (R-IN) and for their acute understanding of the needs of cancer patients. Such licenses have been previously granted to two companies seeking to commercialize Cuban-origin therapeutics in the US and we have ongoing discussions with OFAC in this regard."

 

YM USA previously received a license from OFAC to import nimotuzumab into the US to conduct a study of nimotuzumab in children suffering from recurrent diffuse intrinsic pontine glioma. This trial is ongoing at 10 of the principal oncology hospitals in the US and data is expected in 2010. Nimotuzumab is also available on a compassionate use basis in the US for children with this condition and is designated an Orphan Drug for adult and pediatric glioma by the FDA as well as the EMEA for Europe.

 

Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and developed at the Center of Molecular Immunology in Cuba. The drug has demonstrated efficacy in clinical trials without the serious side effects observed with the marketed EGFR-targeting drugs. Nimotuzumab has been administered to approximately 5,000 patients worldwide and is currently in 32 trials internationally of which 11 are being conducted by YM and its four licensees. Three of the latter are Phase III trials, including one being conducted by the internationally recognized National Cancer Center of Singapore, which selected nimotuzumab over the alternative antibodies because of its benign side effect profile.

 

DANA RESOURCES INCORPORATED (OTCBB: DANR)

"Up 55.00% on Monday"

 

Detailed Quote: http://www.otcpicks.com/quotes/DANR.php  

 

Dana Resources is a precious and base metals exploration company with offices in the United States and Peru. Dana’s management team possesses local knowledge, extensive international connections, a wealth of experience and technical expertise in mining, mining finance, exploration and production. Dana Resources has acquired a portfolio of gold, silver and other precious & base metal properties located in Peru’s most prolific mining regions. With Peru growing as a producer of gold, silver and other metals on the international market, Dana Resources is well positioned to capitalize on the escalating global demand for commodities. The management team and Directors are committed to creating value for their shareholders and to the long-term success of Dana Resources.

 

DANR News:

 

July 29 - Dana Resources Acquires 1.17 Million Ounce Advanced Stage Collota Gold Deposit in Peru

 

Collota Deposit Estimated Resource Totals 1,170,000 Ounces of Gold

 

Dana Resources (OTCBB: DANR) (FRA: OD0), a US-based precious metals exploration and development company, is pleased to announce that it has successfully acquired the advanced stage Collota Gold Deposit in Peru. Dana Resources currently owns and operates seven mining projects located in Peru's most prolific mining regions.

 

The Collota Gold Project is located in Northern Peru in the region of Ancash on the eastern side of the Cordillera Negra, (Black Range Mountains). It is 45km south of the city of Huarez. Elevation ranges from 4,100m to 4,600m.

 

The Collota Gold Project is a high-sulphidation type epithermal gold deposit, positioned in the same trend as Barrick's world famous Pierina mine (originally hosting over 5.2 million ounces of gold and producing as much as 500,000 ounces of gold in 2006). Barrick's Pierina mine is near the end of its resource base. Dana Resources' Collota Gold Project consists of six claims for a total of 4,695 acres.

 

The Collota Gold Deposit is defined by 83 drill holes completed by Buenaventura Mining for a total of 5,500 meters of reverse circulation and diamond core drilling, identifying an initial gold deposit in 281.7 acres. The target area is characterized by intense vuggy silica, quartz-alunite and argillic alteration. The alteration is hosted in the Calipuy group, a suite of volcanic rock characterized by basal andesitic lavas overlying rhyodacitic pumic and lithic tuffs. This particular geology is associated with epithermal gold deposits similar to Pierina and Yanacocha mines. This host rock is identical to Barrick's Pierina deposit. Drilling has indicated attributable resources of 112 million tonnes, defined in two blocks:

 

Oxide Zone - 65 million tonnes with 0.375g/t gold, containing 780,000 oz gold.

 

Sulphide Zone - 47 million tonnes with 0.26 g/t gold, containing 390,000 oz gold.

 

The current estimated resource totals 1,170,000 ounces of gold, equivalent to a current gross in-situ value in excess of $1 Billion. Dana Resources plans to mine the Collota Gold Project as an open-pit mine to a maximum of 50m in depth. The estimated operation costs are approximately $400 per ounce. Further, this geological belt typically hosts economically significant silver resources.

 

Dana Resources is very pleased and excited to complete the acquisition of such a substantial and prolific gold project. The Board of Directors commented, "This is a significant milestone for the Company. Our plan is to simultaneously increase the deposit at Collota and continue permitting the project for production. With only 10% of the Collota Project explored, Dana is confident that there exists a multimillion ounce gold deposit. Dana Resources is confident that this acquisition will yield a significant positive cash flow for Dana Resources and its shareholders upon commencement of commercial production."

 

With some of the richest mineral reserves in the world, Peru is one of the highest producing countries of precious & base metals in Latin America. Previously inaccessible regions are now becoming available through modern technology and equipment, making the high diversity of marketable minerals an extremely attractive prospect. In total, Peru holds about 16 percent of the world's known mineral reserves.

 

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

 

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

 

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

 

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

 

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.

 

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

 

Disclosure: OTCPicks.com has been compensated two thousand five hundred dollars by a third party for DANR advertising and promotional services.